Advanced Enzyme Technologies Limited has announced strong financial results for the quarter and year ended March 31, 2026. The company reported a 22% year-on-year revenue growth in Q4 FY26, reaching ₹2,034 million. On an annual basis, revenue grew by 17% to ₹7,458 million. This performance was driven by robust growth across key business segments, including human nutrition, animal nutrition, and industrial bio-processing, alongside significant improvements in profitability margins.
Quarterly Financial Highlights
For the fourth quarter ended March 31, 2026, Advanced Enzyme Technologies achieved a revenue of ₹2,034 million, representing a 22% increase compared to Q4 FY25. The company’s EBITDA rose by 39% to ₹632 million, while the Profit After Tax (PAT) witnessed a significant uptick of 69%, reaching ₹453 million. These results underscore a strong operational recovery and improved efficiency, with EBITDA and PAT margins standing at 31% and 22% respectively for the quarter.
Annual Growth Performance
On a year-to-date basis, the company delivered consistent growth. Revenue for FY26 grew by 17% to ₹7,458 million. Profitability also showed robust expansion, with EBITDA growing by 18% to ₹2,291 million, and PAT increasing by 30% to ₹1,736 million. The company maintained strong margins for the full year, with EBITDA and PAT margins recorded at 31% and 23% respectively.
Segment Performance
The company’s diverse business segments continued to act as key growth drivers:
- Human Nutrition: This remains the largest segment, contributing 63% of total revenue, with a 15% growth during the year to ₹4,674 million.
- Animal Nutrition: This segment recorded a 25% growth, contributing 13% to the total revenue at ₹946 million.
- Industrial Bio-processing: Contributing 16% of total revenue, this segment grew by 16% during the year, reaching ₹1,176 million.
- Specialized Manufacturing: This segment outperformed with a 23% growth, contributing 9% of the total revenue at ₹662 million.
Future Outlook
Looking ahead, Advanced Enzyme Technologies remains focused on expanding its presence in the human and animal nutrition markets through continued R&D investment and product innovation. The company plans to deepen its geographical reach in key international markets, including the USA, MENA, and Asia, while exploring inorganic expansion opportunities to acquire new technologies and strengthen its competitive position in the global enzyme value chain.
Source: BSE
